Table 3
Open in new tab

Antiarrhythmic drug treatment after recurrence of AF

HF (n = 64)No HF (n = 48)P value
Only sotalol treatment, number (percentage of patients)7 (11)12 (25)0.05
Only amiodarone treatment, number (percentage of patients)18 (28)8 (17)0.16
Amiodarone after sotalol treatment, number (percentage of patients)2 (3)14 (29)<0.001
Number of re-ECVs under AAD, median (range)1 (0–3)1 (0–3)NS
HF (n = 64)No HF (n = 48)P value
Only sotalol treatment, number (percentage of patients)7 (11)12 (25)0.05
Only amiodarone treatment, number (percentage of patients)18 (28)8 (17)0.16
Amiodarone after sotalol treatment, number (percentage of patients)2 (3)14 (29)<0.001
Number of re-ECVs under AAD, median (range)1 (0–3)1 (0–3)NS

AAD, antiarrhythmic drug.

Table 3
Open in new tab

Antiarrhythmic drug treatment after recurrence of AF

HF (n = 64)No HF (n = 48)P value
Only sotalol treatment, number (percentage of patients)7 (11)12 (25)0.05
Only amiodarone treatment, number (percentage of patients)18 (28)8 (17)0.16
Amiodarone after sotalol treatment, number (percentage of patients)2 (3)14 (29)<0.001
Number of re-ECVs under AAD, median (range)1 (0–3)1 (0–3)NS
HF (n = 64)No HF (n = 48)P value
Only sotalol treatment, number (percentage of patients)7 (11)12 (25)0.05
Only amiodarone treatment, number (percentage of patients)18 (28)8 (17)0.16
Amiodarone after sotalol treatment, number (percentage of patients)2 (3)14 (29)<0.001
Number of re-ECVs under AAD, median (range)1 (0–3)1 (0–3)NS

AAD, antiarrhythmic drug.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close